EP1694315A4 - Glycopegylated factor ix - Google Patents

Glycopegylated factor ix

Info

Publication number
EP1694315A4
EP1694315A4 EP04813394A EP04813394A EP1694315A4 EP 1694315 A4 EP1694315 A4 EP 1694315A4 EP 04813394 A EP04813394 A EP 04813394A EP 04813394 A EP04813394 A EP 04813394A EP 1694315 A4 EP1694315 A4 EP 1694315A4
Authority
EP
European Patent Office
Prior art keywords
glycopegylated factor
glycopegylated
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04813394A
Other languages
German (de)
French (fr)
Other versions
EP1694315A2 (en
Inventor
Shawn Defrees
Robert J Bayer
Caryn Bowe
Krishnasamy Panneerselvam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1694315A2 publication Critical patent/EP1694315A2/en
Publication of EP1694315A4 publication Critical patent/EP1694315A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
EP04813394A 2003-12-03 2004-12-03 Glycopegylated factor ix Withdrawn EP1694315A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US53938704P 2004-01-26 2004-01-26
US59274404P 2004-07-29 2004-07-29
US61451804P 2004-09-29 2004-09-29
US62338704P 2004-10-29 2004-10-29
PCT/US2004/041070 WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Publications (2)

Publication Number Publication Date
EP1694315A2 EP1694315A2 (en) 2006-08-30
EP1694315A4 true EP1694315A4 (en) 2009-10-28

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04813394A Withdrawn EP1694315A4 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Country Status (10)

Country Link
EP (1) EP1694315A4 (en)
JP (1) JP4738346B2 (en)
KR (1) KR101209111B1 (en)
AU (1) AU2004296860B2 (en)
BR (1) BRPI0417341A (en)
CA (1) CA2549413A1 (en)
IL (1) IL175661A0 (en)
MX (1) MXPA06006023A (en)
NZ (1) NZ546733A (en)
WO (1) WO2005055950A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
JP2006523211A (en) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド Branched water-soluble polymers and their composites
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (en) 2004-01-08 2016-02-22 Ratiopharm Gmbh O-linked glycosylation of G-CSF peptides
KR101100059B1 (en) 2004-06-30 2011-12-29 넥타르 테라퓨틱스 Polymer-factor ix moiety conjugates
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080080081A (en) * 2005-08-19 2008-09-02 네오스 테크놀로지스, 인크. Glycopegylated factor vii and factor viia
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (en) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー/エス Glycerol-linked PEGylated sugars and glycopeptides
CN103804489A (en) 2006-12-15 2014-05-21 巴克斯特国际公司 Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
BRPI0809670A8 (en) 2007-04-03 2018-12-18 Biogenerix Ag methods to increase stem cell production, to increase the number of granulocytes in an individual, to prevent, treat and alleviate myelosuppression that results from cancer therapy, to treat a condition in an individual, to treat neutropenia and thrombocytopenia in a mammal, to expand hematopoietic stem cells in culture, to increase hematopoiesis in an individual, to increase the number of hematopoietic progenitor cells in an individual, and to provide stable bone marrow graft, and, oral dosage form.
US20100081187A1 (en) * 2007-04-26 2010-04-01 Griffith Michael J Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
MX2009013259A (en) 2007-06-12 2010-01-25 Novo Nordisk As Improved process for the production of nucleotide sugars.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN102026653B (en) * 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 Human factor IX variants with an extended half life
KR20100110799A (en) * 2007-12-27 2010-10-13 백스터 인터내셔널 인코포레이티드 Chemically modified factor ix
DK2257311T3 (en) 2008-02-27 2014-06-30 Novo Nordisk As Conjugated Factor VIII Molecules
MX2010011345A (en) * 2008-04-16 2011-02-23 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof.
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
PL2459224T3 (en) 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
MX2012001346A (en) * 2009-07-31 2012-02-17 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof.
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
EP3552619A1 (en) 2010-07-09 2019-10-16 Bioverativ Therapeutics Inc. Factor ix polypeptides and methods of use thereof
HUE049352T2 (en) 2010-12-22 2020-09-28 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
EP3941509A1 (en) 2019-03-19 2022-01-26 CSL Behring Lengnau AG Factor ix variants and uses thereof in therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (en) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP1260582A1 (en) * 1995-09-29 2002-11-27 Biovitrum Ab Conjugates of factor IX and a biocompatible polymer
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00005376A (en) * 1997-12-01 2002-07-02 Neose Technologies Inc Enzymatic synthesis of gangliosides.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (en) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP1260582A1 (en) * 1995-09-29 2002-11-27 Biovitrum Ab Conjugates of factor IX and a biocompatible polymer
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUDZIAK G ET AL: "Cyclodextrin-assisted Glycan Chain Extension on a Protected Glycosyl Amino Acid", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 32, 4 August 2000 (2000-08-04), pages 5865 - 5869, XP004229184, ISSN: 0040-4020 *

Also Published As

Publication number Publication date
WO2005055950A2 (en) 2005-06-23
AU2004296860B2 (en) 2010-04-22
JP2007513190A (en) 2007-05-24
BRPI0417341A (en) 2007-04-17
EP1694315A2 (en) 2006-08-30
JP4738346B2 (en) 2011-08-03
KR20060123224A (en) 2006-12-01
NZ546733A (en) 2009-07-31
AU2004296860A1 (en) 2005-06-23
KR101209111B1 (en) 2012-12-06
WO2005055950A3 (en) 2005-10-20
IL175661A0 (en) 2006-09-05
CA2549413A1 (en) 2005-06-23
MXPA06006023A (en) 2006-08-23

Similar Documents

Publication Publication Date Title
IL175661A0 (en) Glycopegylated factor ix
DE602004023400D1 (en) Lies
IL175660A0 (en) Glycopegylated erythropoietin
DE502004011703D1 (en) N-heterocyclyl-phenylsubstituierte cyclische ketoenole
DE602004012071D1 (en) T-hilfe
DE602004020356D1 (en) Phenoxyessigsäurederivate
DE602004030538D1 (en) Präzisionssubstratlagerbehälter
SG133617A1 (en) General electric company
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
AU155161S (en) Case
DE502004003476D1 (en) Standfuss
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
DE502004011852D1 (en) Nspritzventil
DE502004004146D1 (en) Pyrazolverbindungen
GB0311208D0 (en) Feature based caricaturing
DE602004012262D1 (en) Benzimidazolonverbindung
DE502004011343D1 (en) Rotorspinnmaschine
DE112004002769D2 (en) Schienengeführtes transportsystem
DE602004020525D1 (en) Imidazolderivate
DE502004012153D1 (en) Rotorspinnmaschine
EP1614695A4 (en) Polypeptide
DE10394343D2 (en) Berührungslose biometrische erkennung
AU155596S (en) Case
TW559446U (en) Case structure
ZA200706129B (en) Glycopegylated Factor IX

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060630

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20060731

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20060731

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEOSE TECHNOLOGIES, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVO NORDISK A/S

A4 Supplementary search report drawn up and despatched

Effective date: 20090924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101AFI20090918BHEP

Ipc: C07K 14/745 20060101ALI20090918BHEP

17Q First examination report despatched

Effective date: 20101029

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160502

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160914